LRMR logo

LRMR
Larimar Therapeutics Inc

4,926
Mkt Cap
$358.4M
Volume
1.13M
52W High
$6.42
52W Low
$1.80
PE Ratio
-1.66
LRMR Fundamentals
Price
$3.45
Prev Close
$3.57
Open
$3.60
50D MA
$4.38
Beta
1.63
Avg. Volume
1.33M
EPS (Annual)
-$2.26
P/B
2.28
Rev/Employee
$0.00
$146.10
Loading...
Loading...
News
all
press releases
Larimar Therapeutics, Inc. $LRMR Shares Acquired by AIGH Capital Management LLC
AIGH Capital Management LLC lifted its stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 100.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000,000 shares of the compa...
News Placeholder
More News
News Placeholder
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have...
News Placeholder
Larimar Therapeutics (LRMR) to Release Earnings on Wednesday
Larimar Therapeutics (NASDAQ:LRMR) will be releasing its Q1 2026 earnings before the market opens on Wednesday, April 29. (View Earnings Report at...
News Placeholder
Q1 Earnings Estimate for LRMR Issued By Lifesci Capital
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at Lifesci Capital issued their Q1 2026 EPS estimates for Larimar Therapeutics in a report issued on Wednesday, April 1st...
News Placeholder
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have received an average recommendation of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat.com...
News Placeholder
Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday
Larimar Therapeutics (NASDAQ:LRMR) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-larimar-therapeutics-inc-stock...
News Placeholder
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade...
News Placeholder
Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00
Wedbush lifted their price target on shares of Larimar Therapeutics from $12.00 to $13.00 and gave the stock an "outperform" rating in a research note on Friday...
News Placeholder
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Sees Significant Decrease in Short Interest
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) saw a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 7,692,689...
News Placeholder
Mangrove Partners IM LLC Sells 327,997 Shares of Larimar Therapeutics, Inc. $LRMR
Mangrove Partners IM LLC decreased its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 42.6% during the third quarter, according to its most recent disclosure with the...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available